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Background 
Antiplatelet therapy is widely used in secondary prevention after cerebral 
ischaemia, but is associated with increased bleeding. The S2TOP-BLEED score 
predicts major bleeding with chronic antiplatelet therapy and is tested here in 
acute stroke using data from the TARDIS trial. 
 
Methods 
The international TARDIS trial assessed the safety and efficacy of intensive 
(combined aspirin, dipyridamole and clopidogrel) versus guideline 
(aspirin/dipyridamole, or clopidogrel alone) antiplatelets given for one month in 
3096 patients with acute stroke or TIA. The S2TOP-BLEED score was derived 
from age; sex; ethnicity; premorbid modified Rankin Scale (mRS); history of 
smoking, prior stroke, diabetes or hypertension; weight; and antiplatelet regime. 
Triple antiplatelet therapy was scored as for combined aspirin and clopidogrel. 
Data are number (%), median [interquartile range], or mean (standard 
deviation). 
 
Results 
S2TOP-BLEED scores were available for 2893 (93.4%) patients: mean age 68.9 
(10.1) years, male 1886 (63.2%), Caucasian 2834 (95.0%), smoking 770 
(25.8%), prior stroke 338 (11.3%), diabetes 563 (18.9%), hypertension 1753 
(58.8%), premorbid mRS ≥3 2 (0.1%), estimated weight 75.4 (16.6) kg. 1493 
patients were randomised to triple antiplatelet therapy, and 1490 to guideline: 
817 (54.8%) clopidogrel and 673 (45.2%) aspirin/dipyridamole. S2TOP-BLEED 
scores ranged from 2 to 24, mean 11.8 (3.8), median 12 [9-14]. Major bleeding 
(54, 1.8% patients by day 90) increased with S2TOP-BLEED score: 0-5, 0 (0%); 
6-10, 11 (1.2%); 11-15, 30 (2.1%); >15, 13 (2.8%); p=0.0057 for trend. 
 
Conclusions 
The S2TOP-BLEED score appears to predict major bleeding by day 90 in patients 
on antiplatelets after acute non-cardioembolic cerebral ischaemia. 
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